Literature DB >> 17340229

Imaging non-dopaminergic function in Parkinson's disease.

David J Brooks1.   

Abstract

In Parkinson's disease (PD), there is degeneration of the cholinergic, noradrenergic, and serotonergic systems in addition to dopaminergic projections. Function of these non-dopaminergic systems can be imaged with positron emission tomography (PET) and single photon emission computed tomography (SPECT) and correlated with motor and nonmotor symptomatology. In addition, neuronal loss in PD is associated with microglial activation. The role of microglia in driving the disease process remains uncertain. This review presents and discusses current findings in these areas.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17340229     DOI： 10.1007/s11307-007-0084-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN： 1536-1632            Impact factor:   3.484


  31 in total

1.  [N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy.

Authors:  Georg Berding; Christoph H Schrader; Thomas Peschel; Jörg van den Hoff; Hans Kolbe; Geerd J Meyer; Reinhard Dengler; Wolfram H Knapp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-09       Impact factor: 9.236

2.  Microglial activation and dopamine terminal loss in early Parkinson's disease.

Authors:  Yasuomi Ouchi; Etsuji Yoshikawa; Yoshimoto Sekine; Masami Futatsubashi; Toshihiko Kanno; Tomomi Ogusu; Tatsuo Torizuka
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

3.  Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine.

Authors:  Yu-Shin Ding; Kuo-Shyan Lin; Jean Logan; Helene Benveniste; Pauline Carter
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

4.  Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy.

Authors:  M Yoshita
Journal:  J Neurol Sci       Date:  1998-02-18       Impact factor: 3.181

5.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

6.  Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.

Authors:  P Piccini; R A Weeks; D J Brooks
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

7.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains.

Authors:  Kazuhiro Imamura; Nozomi Hishikawa; Makoto Sawada; Toshiharu Nagatsu; Mari Yoshida; Yoshio Hashizume
Journal:  Acta Neuropathol       Date:  2003-09-25       Impact factor: 17.088

8.  Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET.

Authors:  Anthony K P Jones; Hiroshi Watabe; Vin J Cunningham; Terry Jones
Journal:  Eur J Pain       Date:  2004-10       Impact factor: 3.931

9.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

10.  Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.

Authors:  I Litvan; A MacIntyre; C G Goetz; G K Wenning; K Jellinger; M Verny; J J Bartko; J Jankovic; A McKee; J P Brandel; K R Chaudhuri; E C Lai; L D'Olhaberriague; R K Pearce; Y Agid
Journal:  Arch Neurol       Date:  1998-07
View more
  5 in total

Review 1.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 2.  Assessment of the progression of Parkinson's disease: a metabolic network approach.

Authors:  Thomas Eckert; Chengke Tang; David Eidelberg
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

Review 3.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

4.  Mathematical insights into the effects of levodopa.

Authors:  Michael C Reed; H Frederik Nijhout; Janet A Best
Journal:  Front Integr Neurosci       Date:  2012-07-04

Review 5.  Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.

Authors:  Peter Jenner; Huw R Morris; Trevor W Robbins; Michel Goedert; John Hardy; Yoav Ben-Shlomo; Paul Bolam; David Burn; John V Hindle; David Brooks
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.